BIOCORP Production

Novo Nordisk entered exclusive negotiations to acquire a controlling stake in BIOCORP, a French medical device company, from main shareholder BIO JAG, representing 45.3% of share capital, at €35 per share. This will be followed by a mandatory tender offer for all remaining shares, valuing BIOCORP at approximately €154 million.